Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going forward, reflecting continued strong execution on its ...

Trinity Biotech plc announced that it has achieved Adjusted EBITDA-positive operations during Q2 2025 and expects to maintain this positive trajectory going forward, marking a key milestone in its ...

Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements. Story Continues Contact: Trinity Biotech plc RedChip Companies Inc. Micheal Roche ...

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. Our current products are used to detect a ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), currently trading at $0.55 per share with a market capitalization of approximately $10 million, has received World Health Organization approval for ...

DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the ...

Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), currently trading at $0.55 per share with a market capitalization of approximately $10 million, has received World Health Organization approval for ...